ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,277.51
      0.80%
      US Tech 100
      18,064.80
      0.02%
      Dow Jones
      38,686.32
      1.51%
      Brent Oil
      81.295
      0.00%
      Bitcoin
      67,702.38
      0.33%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Genmab AS (GMAB)

      7. Genmab AS (GMAB) News

      GMAB

      Genmab AS (GMAB)

      Genmab AS
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:GMAB
      DateTimeSourceHeadlineSymbolCompany
      06/01/202410:00AMBusiness WireInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)NASDAQ:GMABGenmab AS
      05/28/202411:29AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      05/23/20245:00PMBusiness WireGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:GMABGenmab AS
      05/21/202411:38AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      05/21/202411:18AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      05/21/202411:10AMBusiness WireGenmab Completes Acquisition of ProfoundBioNASDAQ:GMABGenmab AS
      05/14/202410:05AMBusiness WireGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) CongressNASDAQ:GMABGenmab AS
      05/13/202411:29AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      04/29/20246:40PMBusiness WireTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
      04/29/20246:40PMBusiness WireFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
      04/03/20241:35AMBusiness WireGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioNASDAQ:GMABGenmab AS
      03/11/20241:43PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      03/04/20241:50PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      03/04/20241:26PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      03/01/20245:04PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GMABGenmab AS
      02/29/202411:47AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      02/28/202411:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      02/27/20244:55PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      02/27/20247:45AMBusiness WireU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
      02/26/202412:19PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      02/26/202410:40AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      02/22/20244:28PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GMABGenmab AS
      02/20/202411:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      02/14/20243:42PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      02/14/20241:49PMEdgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:GMABGenmab AS
      02/14/202412:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      02/02/20246:45AMBusiness WireTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
      01/31/202411:17AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      01/23/20249:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
      01/09/20247:45AMDow Jones NewsPfizer, Genmab Get Speedy FDA Review of Tivdak Full ApprovalNASDAQ:GMABGenmab AS
       Showing the most relevant articles for your search:NASDAQ:GMAB